Elesclomol (STA-4783)

For research use only.

Catalog No.S1052

9 publications

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 1770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Elesclomol (STA-4783) has been cited by 9 publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHCVJNKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?= MUfTRW5ITVJ?
CAL-51 cell NULlXmk6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jzWWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= M{jWO3NCVkeHUh?=
ABC-1 cell NU\oTHFTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFe3ZYNKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjVibl2= MUfTRW5ITVJ?
A2780 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MkPiV2FPT0WU
ES1 cell M4Oyd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{XtdGlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NXLEZmVFW0GQR1XS
HUTU-80 cell M4TFXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPDTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2= MULTRW5ITVJ?
NCI-H292 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjWTZpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> Mon6V2FPT0WU
NB69 cell M2flbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DjeWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? M2\UOnNCVkeHUh?=
ES8 cell NX60O2E3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XRfWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNkBvVQ>? M{HQSnNCVkeHUh?=
BCPAP cell MlLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TrUGlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1KG6P MofaV2FPT0WU
T-24 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXvVXVRtUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PSCwTR?= NGnxPZNUSU6JRWK=
EW-16 cell NILtbYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? MXfTRW5ITVJ?
OVCAR-5 cell M2DTS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLGTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= M2C4WHNCVkeHUh?=
SF126 cell NIL3S4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkPSTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? NGjCfGFUSU6JRWK=
KP-4 cell NGrxfZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XDZ2lvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? NFvnVlNUSU6JRWK=
GAMG cell NGTCSJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O NX7BcHpvW0GQR1XS
HOS cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUOgcm0> MXnTRW5ITVJ?
CHL-1 cell M1;kd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHrWFdKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= NV3tSVhUW0GQR1XS
AGS cell MnP5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOE[gcm0> NGjRN|hUSU6JRWK=
MDA-MB-157 cell NGWycW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NI\4[|RKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O NYjneVhyW0GQR1XS
HSC-3 cell M3qxfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGD3W4JKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= Mn3LV2FPT0WU
CAL-72 cell M1joW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rTZ2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= M3njRXNCVkeHUh?=
NBsusSR cell MmTES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P NUjuPIdVW0GQR1XS
ES7 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XzNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61PUBvVQ>? M4HrWnNCVkeHUh?=
H-EMC-SS cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFTL[W1KdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> M4HYPXNCVkeHUh?=
NCI-H1703 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUewN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= MVzTRW5ITVJ?
BHT-101 cell NX;QfnpvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\JeG51UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55MjDuUS=> NVH4[41bW0GQR1XS
SK-OV-3 cell MlrqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn2zTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44PSCwTR?= NXG1bWVDW0GQR1XS
EW-24 cell M1jy[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXqTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? M3XlT3NCVkeHUh?=
PSN1 cell NUfRNHc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGOxdG9KdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg1KG6P MUTTRW5ITVJ?
OVCAR-8 cell MlP3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\HWGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= NEPrOJpUSU6JRWK=
NCI-H1563 cell M{i4Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= NX7QWIdzW0GQR1XS
SW756 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NELUcW9KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?= MXzTRW5ITVJ?
A375 cell NEPiOYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{TNd2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVQhdk1? M4n2OnNCVkeHUh?=
Ca9-22 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MofrTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P MnPkV2FPT0WU
SW1990 cell NVHlVVZDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmDITY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P MVfTRW5ITVJ?
ES4 cell NWW0N2VnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXERXBIUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM6KG6P NHHJN|lUSU6JRWK=
HCE-T cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTEPWNqUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2= M1S4S3NCVkeHUh?=
MOLT-16 cell MnXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3G5[GlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPTNibl2= NFrP[o9USU6JRWK=
HSC-4 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\WOHdmUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?= NWG5V2NDW0GQR1XS
NCI-SNU-1 cell NVn3V3B1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDZibl2= M1HGc3NCVkeHUh?=
EW-11 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1W2NGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1? M13zdnNCVkeHUh?=
HT-1080 cell NEnFbmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPCSVVKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N MXHTRW5ITVJ?
MES-SA/Dx5 cells NIfpco1EgXSxdH;4bYNqfHliYYPzZZk> MnvhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N NY\VV2d3OjN7M{e5PFE>
SW1710 cell NYLmd2N6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHviUGVKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= NGTRRXBUSU6JRWK=
EW-1 cell Mn7jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\OTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yOEBvVQ>? Mm[yV2FPT0WU
BV-173 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvCTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P MUfTRW5ITVJ?
TE-8 cell M1TpcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEjnRWZKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQyKG6P NUfVTINZW0GQR1XS
G-401 cell M13oSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmjhTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFMhdk1? MVHTRW5ITVJ?
KOSC-2 cell MnKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3fT[WlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= NHr6[phUSU6JRWK=
HuCCT1 cell NFTodXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPmNFZKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTJibl2= MWDTRW5ITVJ?
FADU cell MlTYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJGZCTFViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2JI5O Mn;VV2FPT0WU
MHH-ES-1 cell NEGyOGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?= NYfLUGlWW0GQR1XS
ES3 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2f6RmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PUBvVQ>? M1fz[XNCVkeHUh?=
OVCAR-4 cell MmTWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWf1[VlrUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> MnjDV2FPT0WU
HD-MY-Z cell NYP4[ZNGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk[5TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?= MY\TRW5ITVJ?
human JAR cell NHzkXIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPkR|ZCUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk4KG6P Mli2V2FPT0WU
A427 cell NYfFSFFST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3HTXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNFchdk1? MlfaV2FPT0WU
697 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMUOgcm0> MoflV2FPT0WU
OVCAR-3 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;BWlBSUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N NUXudYhVW0GQR1XS
human NB14 cell NFXzd5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Lk[0JI5O MkDUV2FPT0WU
GB-1 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoLuTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? NHPMW|RUSU6JRWK=
COR-L105 cell NWnGeYUxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\yZmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njd4IH7N NYPLdlR1W0GQR1XS
647-V cell MnHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFXrXotKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P MVPTRW5ITVJ?
human K5 cell NF\QV5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjWdHdRUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUegcm0> MonYV2FPT0WU
DMS-273 cell NXjudm9VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnu4TY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= MoLuV2FPT0WU
UM-UC-3 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P M4TV[HNCVkeHUh?=
HEL cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLPNI0{UW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P Mmr6V2FPT0WU
human KU-19-19 cell NETUfmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPoZ5F4UW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> MVHTRW5ITVJ?
MC-IXC cell NYfm[oJiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3m2bGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= MYHTRW5ITVJ?
human H4 cell NGDwV|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkLRTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMkWgcm0> MkToV2FPT0WU
NUGC-3 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3jnTmlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{OyCwTR?= M4C5PXNCVkeHUh?=
CHP-212 cell NEDlTFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P M2W5[XNCVkeHUh?=
human SW982 cell NXLUZ3dGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3MZmVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= NX\qS4J{W0GQR1XS
C-33-A cell MkLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXUPHZNUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N MoLJV2FPT0WU
PC-3 cell M2TZPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrQTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVQ>? M2K5e3NCVkeHUh?=
COLO-684 cell NHXKOoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7rTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= M4SzW3NCVkeHUh?=
SNU-387 cell M2jGNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\TTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?= NFT6SY5USU6JRWK=
U251 cell NY\r[I9oT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O MUDTRW5ITVJ?
A673 cell NEfwXnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjGdohKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NGrITYRUSU6JRWK=
human T47D cell M164bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjvTY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MU[uO|khdk1? NVnjdVVOW0GQR1XS
A549 cell M1LMbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O MVrTRW5ITVJ?
PC-14 cell NWXpZlhJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\sT2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?= Mm\yV2FPT0WU
A704 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? NGDjTFJUSU6JRWK=
MCF7 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\uTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? NWrIPZhPW0GQR1XS
PC3 cells M136dmZ2dmO2aX;uJIF{e2G7 MnezTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> MYqyNVM1OTZ5NR?=
F-36P cells MoXkVJJwdGmoZYLheIlwdiCjc4PhfS=> M{nvXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? MVuyNVM1OTZ5NR?=
OCI-AML2 cells NYLZ[I9FWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGXRNWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN NE[1VnkzOTN2MU[3OS=>
K562 cells M2\MUXBzd2yrZnXyZZRqd25iYYPzZZk> M2XEdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczygTWM2OD1zODFOwG0> NGK5ZoszOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A
Smiles CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID